Liminal Biosciences

Liminal Biosciences Inc. (www.liminalbiosciences.com) is a preclinical-stage biopharmaceutical company that recently acquired AmorChem’s spin-out company Fairhaven Pharmaceuticals Inc. (“Fairhaven”) and its preclinical research program of small molecule antagonists for respiratory and gastrointestinal eosinophilic-driven diseases.
Fairhaven’s R&D program is based on the collaborative research of Dr. William Powell, Professor Emeritus in the Department of Medicine at McGill University, and Dr. Joshua Rokach of the Florida Institute of Technology. Drs. Powell and Rokach developed a series of potentially first-in-class, oral, selective OXE receptor antagonists against 5-oxo-ETE, one of the most potent human eosinophil chemoattractants.